Search Results - chemotherapy

3 Results

Sort By:

Increased Therapeutic Effectiveness of PE-Based Immunotoxins

Abstract: Patients receiving immunotoxin cancer therapy are less likely to experience the deleterious side-effects associated with non-discriminate therapies such as chemotherapy or radiation therapy. Unfortunately, the continued administration of immunotoxins often leads to a reduced patient response due to the formation of neutralizing antibodies...

Published: 5/14/2025 | Updated: 8/2/2023 | Inventor(s): Ira Pastan, Masanori Onda, Wenhai Liu

Keywords(s): B-CELL, CHEMOTHERAPY, Human B cell epitopes, Immunogenic epitopes, Immunotoxin, Pseudomonas exotoxin A, T-cell

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues

Summary: NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents. Description of Technology: Topoisomerase enzymes play an important role in cancer progression by controlling changes...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Barry O'Keefe, Lauren Krumpe, Johan Rosengren, Ingrid Schroeder, Alan Bermingham, Christophe Marchand, Kirk Gustafson, Brice Wilson, Yves Pommier

Keywords(s): CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

Angiogenesis-Based Cancer Therapeutic

Abstract: Vascular Endothelial Growth Factor-A (VEGF-A) is an angiogenic agent that drives blood vessel formation in solid tumors and other diseases, such as macular degeneration and diabetic retinopathy. Several therapies that target the ability of VEGF to stimulate angiogenesis have been approved. These therapies regulate VEGF-A activity by binding...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Donald Bottaro, Fabiola Cecchi

Keywords(s): ANGIOGENESIS, CHEMOTHERAPY, Diabetic Retinopathy, FLT-1, Heparin sulfate proteoglycan, Hepatocyte growth factor (HGF), KDR/FLK-1, Macular degeneration, VEGF-A

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing